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Tor Signaling Senses Nutrients and Growth
Factors to Govern Pathways Involved in the
Pathogenesis of Fungi, Parasites, and Viruses
In eukaryotes from yeast to humans, the Tor signaling cascade
responds to nutrients and growth factors to orchestrate cell growth
and proliferation. The central elements of this signaling cascade
are the Tor protein kinases, which are the targets of the potent
anti-proliferative and immunosuppressive natural product rapa-
mycin [1]. Most organisms, including mammals, express a single
Tor kinase; however, the yeasts Saccharomyces cerevisiae and
Schizosaccharomyces pombe contain two Tor homologs [2], and three
and four (two classical Tor kinases and two Tor-like kinases) have
been identified in the protozoans Leishmania major and Trypanosoma
brucei, respectively [3,4]. The Tor kinases interact with other
proteins to form two distinct and ubiquitously conserved
complexes known as TORC1 and TORC2 (reviewed in [5]).
Under optimal nutrient conditions, TORC2 drives actin polari-
zation, whereas TORC1 promotes ribosome biogenesis and
protein translation conducive to cell growth and proliferation
while suppressing autophagy. In general, TORC1 is rapamycin
sensitive in contrast to TORC2, which is resistant to rapamycin
with the exception noted below for T. brucei [4,6]. This report
discusses recent studies uncovering emerging roles for Tor
signaling in promoting fungal and protozoan pathogen growth
and proliferation tailored to invade and colonize the host.
Moreover, protozoans and viruses have also developed strategies
to subvert the host Tor signaling cascade and thereby comman-
deer the translational machinery to evade the immune system and
promote viral protein synthesis, respectively.
Tor Regulates Cell–Cell Adhesion in Candida
albicans
Candida albicans is the most common opportunistic fungal
pathogen of humans, causing skin and mucosal infections as well
as potentially fatal systemic infections. Cell–cell adhesion is
necessary for C. albicans to form biofilms, an important feature of
its pathogenicity repertoire. Interestingly, Tor1 regulates the
expression of several cell wall– and hyphal-specific genes,
including adhesins and their transcriptional regulators, which
elicit biofilm formation in C. albicans [7].
Exposure of C. albicans to rapamycin results in upregulation of
the transcriptional activators Bcr1 and Efg1 as well as downreg-
ulation of the transcriptional repressors Nrg1 and Tup1, which
control adhesin genes [7]. These effects correlate with expression
of hyphal-induced genes, including those encoding the adhesins
Als1, Als3, and Hwp1 and the gene encoding the cell wall protein
Ece1. Importantly, Als1, Als3, and Hwp1 mediate cellular
adhesion to a variety of host surfaces and facilitate adhesion
during biofilm formation (reviewed in [8]).
Tor1 also regulates morphogenesis and cellular aggregation,
which have implications for the pathogenicity and virulence of C.
albicans. These effects appearto beatleast inpart mediated byMds3,
which is a regulator of morphogenetic processes such as the yeast to
hyphal transition and biofilm formation [9,10]. Although at present
it is unclear how Mds3 acts, it has been suggested that Mds3 is a
negative regulator of Tor1 [11]. Treatment with the Tor inhibitor
rapamycin inhibits hyphal growth on solid media and causes
extensive cellular aggregation and flocculation. These results are
consistent with the model that Tor1 positively controls filamentation
and negatively regulates cellular adhesion (Figure 1A) [7].
Rapamycin Potently Inhibits Trypanosome
Proliferation by Blocking TORC2 Assembly
T. brucei is a protozoan parasite responsible for causing
,500,000 annual infections in Africa that result in sleeping
sickness, with devastating socioeconomic effects. T. brucei has a
complex life cycle that develops in two different hosts (the tsetse fly
and vertebrates) and several niches within these hosts. Nutritional
stress encountered in the insect triggers the development of the
non-infectious procyclic trypomastigote into the infective metacy-
clic trypomastigote. In addition, nutritional stress also induces
adhesion of the parasite to the digestive tract of the insect [12].
Once a trypanosome is delivered into the favorable conditions of
vertebrate blood, the epimastigote develops into the bloodstream
form of the parasite and rapidly proliferates to establish a
successful infection (reviewed in [13]).
Recent studies have shown that Tor signaling profoundly
impacts the growth and development of T. brucei. Two classical
Tor1 and Tor2 proteins, as well as two Tor-like proteins, have
been identified in T. brucei [4]. The tbTor1 kinase associates with
TORC1 and controls protein synthesis and cell size while the Tor-
like 1 protein regulates autophagy [4,14,15]. The tbTor2 kinase
populates TORC2 and, in contrast to the paradigm established in
other organisms, tbTORC2 is sensitive to rapamycin, whereas
tbTORC1 is resistant to rapamycin. tbTORC2 is involved in
driving polarized cell growth, endocytosis, and cytokinesis [4].
Trypanosome cells have a highly polarized microtubular
network that enables endocytosis and exocytosis to occur at a
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network compromises endocytosis with fatal consequences for the
organism. Accordingly, either tbTor2 depletion or rapamycin
exposure (which prevents tbTORC2 formation) results in aberrant
cell morphology with an enlarged flagellar pocket, actin cytoskel-
eton depolarization, impaired endocytosis, and a block to
cytokinesis [4]. Interestingly, rapamycin treatment of the T. brucei
bloodstream form cultured in vitro markedly inhibits cell
proliferation. Thus, it has been suggested that therapy with less
immunosuppressive rapamycin analogs could be highly efficacious
against trypanosomiasis [4].
Leishmania major Hijacks the Host Translational
Machinery via mTor Proteolysis
The protozoan parasite L. major is the etiologic agent for
leishmaniasis and, similar to trypanosomes, develops as promas-
tigotes in the midgut of sandflies and as amastigotes within
macrophages of the vertebrate host. L. major contains three Tor
homologs, at least one of which (Tor3) is required for macrophage
infectivity and virulence [3].
mTOR-dependent translation of type I interferon (IFN) is critical
for triggering host innate immune responses to defend against
infection, including those caused by parasites [16,17]. Interestingly,
L. major hijacks the host translational machinery via disruption of
mTor signaling, thereby enhancing parasite infectivity [18]. The L.
major surface glycoprotein GP63, which exhibits Zn-dependent
protease activity, is associated with L. major virulence. GP63 directly
or indirectly promotes mTor cleavage, resulting in mTORC1
inhibition. This event prevents mTORC1-dependent phosphoryla-
tion and inactivation of host 4E-binding protein 1 (4E-BP1).
Activated 4E-BP1 forms a physical complex with the mRNA cap
binding factor eIF4E (elongation initiation factor 4E), thereby
blocking the ability of eIF4E to assemble into the eIF4F complex
and cap-dependent translation (reviewed in [19]). In parallel, type I
IFN expression, which is deployed by the host immune system to
defend against L. major, is decreased, though it is not yet clear what
directly causes this phenomenon. Moreover, either rapamycin
treatment or 4E-BP1 and 4E-BP2 knockout results in increased type
I IFN expression and reduced L. major parasite load in mice. Thus,
host mTORC1 is inactivated by L. major GP63 to promote parasite
survival within host macrophages (Figure 1B). This model has led to
the suggestion that host 4E-BP1/2 could be targeted therapeutically
to treat leishmaniasis [18].
Viruses Activate mTor-Dependent Translation to
Ensure Infection
Viruses depend on the cellular protein synthesis machinery for
viral protein translation. In particular, poxivirus, adenovirus, and
human herpes virus mRNA translation is heavily dependent upon
mTor to inactivate the repressor 4E-BP1 and thus enable eIF4F
cap-dependent translation (reviewed in [19,20]). Growth factors
activate mTor via the AKT-kinase, TSC1/2, Rheb-GTPase
signaling module (Figure 1C). In response to growth factors,
AKT phosphorylates the tuberous sclerosis heterodimer TSC1/2,
thereby inactivating its GTPase activating protein (GAP) activity,
which results in the active Rheb
GTP form and, in turn, mTor
activation (reviewed in [21]). Interestingly, herpes and other
viruses have developed multiple mechanisms to activate mTor and
ensure sustained viral protein translation (Figure 1C). Epstein-Barr
virus (EBV) and Kaposi’s sarcoma herpes virus (KSHV) encode
the proteins LMP2A and G protein–coupled receptor vGPCR,
respectively, which activate AKT [22,23]. The human cytomeg-
alovirus (HCMV) UL38 protein and the human papilloma virus
(HPV) E6 oncoprotein antagonize TSC2 [24].
Remarkably, the herpes simplex virus (HSV-1) Us3 kinase acts
as an AKT surrogate capable of phosphorylating and inactivating
TSC2, resulting in constitutive mTORC1 activation [25]. These
results suggest that mTor inhibition should prevent viral
Figure 1. Tor signaling governs key processes that dramatically impact pathogenesis of fungi, parasites, and viruses. (A) caTor1
controls gene expression of adhesins and their upstream regulators, which elicit cell–cell adhesion, a process required for biofilm formation and host
niche colonization. (B) The L. major GP63 cell surface protease promotes mTor cleavage and thereby mTORC1 inactivation. This event prevents
mTORC1-dependent IFN type I translation, which dampens the host immune response and results in high parasite cell load. (C) Many human viral
pathogens rely upon mTORC1 cap-dependent translation for replication. Growth factors activate mTORC1 via the phosphatidylinositol 3-kinase
(PI3K), AKT, TSC1/2, Rheb signaling module (see text for details). Viruses have evolved protein factors capable of stabilizing the Rheb
GTP active form
by either activating AKT or inactivating TSC2. Rheb
GTP activates mTORC1, enabling cap-dependent translation of early viral transcripts, which leads to
viral replication.
doi:10.1371/journal.ppat.1002269.g001
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Torin1 potently blocks herpes virus replication, particularly during
the early phase of viral infection [26,27]. The Torin1 studies also
revealed that the role of mTor activation during HCMV infection
is not confined to inactivating 4E-BP1 or exclusive to the
rapamycin-sensitive mTORC1, and additional targets within the
mTORC1 and mTORC2 pathway components await elucidation.
Future Directions
The dramatic impact of nutrients as the triggers for morpho-
genic transitions that promote infection and host colonization in
fungi and parasites, as well as the dependence of viral replication
on the cellular translational machinery, prompted studies to
investigate the roles of the Tor signaling cascade in these diverse
infectious processes. Not surprisingly, the exciting results with
pathogenic fungi, parasites, and viruses have thus far opened new
avenues for further study. Recent studies with the Salmonella
effector protein AvraA, which is conserved in Yersinia pathogenic
species, suggest that bacteria have also developed strategies to
target host signaling cascades (including mTor) to control gene
expression and promote virulence [9]. Moreover, there is growing
evidence that Tor-regulated processes such as autophagy have
dramatic impact on virulence. In particular, it is well established
that autophagy can destroy invading pathogens (a process also
known as xenophagy) and enhances innate immunity, protecting
cells and organisms against infection by a wide range of pathogens,
including bacteria, viruses, and parasites (reviewed in [28]). Thus,
we can expect that future studies in these arenas will continue to
illuminate novel aspects of Tor signaling in microbial pathogenesis
that will stimulate the development of new Tor-based therapies to
combat infection.
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